Our Work in Neurology
Specialized patient populations that require unique or complex therapies will continue to make neurology the target for dynamic research and commercial markets. With a specific focus on the multiple sclerosis (MS) market in the US and the EU, Spherix is shedding light on the key dynamic issues in this fast moving category as the increased risk tolerance and the expanding number of therapies evolves the treatment strategies for all forms of MS.
Multiple Sclerosis, Rare Neurological Diseases
Board of Advisors
The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with MS and those who are close to them.
FDA Approval of Mylan’s Glatiramer Acetate Will Turn the Payer Pressure On for Teva’s Copaxone and Sandoz’s Glatopa – October 4, 2017
First-in-Class PPMS Indication Fueling Much of the Adoption of Genentech’s Ocrevus, but Insurance Coverage Issues Could be a Looming Stumbling Block – September 19, 2017
Early Uptake of Roche/Genentech’s Ocrevus Off to Stellar Start, According to Latest Quarterly Update from Spherix Global Insights – July 19, 2017
2017 ECTRIMS Meeting
2018 ACTRIMS Meeting